Objective: Early diagnosis and treatment initiation significantly influence long-term disability outcome in multiple sclerosis (MS). We aimed at identifying prodromal symptoms of MS in primary care settings. Methods: This was a nested case-control study comparing the occurrence of various symptoms in MS patients versus controls at 0 to 2, 2 to 5, and 5 to 10 years before index date (first MS record . Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using conditional logistic regression. Results: MS patients had significantly higher risk of presenting up to 10 years prior to index date with gastric, intestinal, urinary, and anorectal disturbances, anxiety, depression, insomnia, fatigue, headache, and various types of pain. MS risk progressively increased with each additional symptom presented (0-2 years: OR 5 1.51, 95% CI 5 1.47-1.55, p < 0.001; 2-5 years: OR 5 1.29, 95% CI 5 1.25-1.33, p < 0.001; 5-10 years: OR 5 1.20, 95% CI 5 1.15-1.26, p < 0.001). Sensitivity analyses in patients with age at index < 40 years and no neurological disturbances prior to symptoms of interest showed consistent results. Interpretation: Various clinical disturbances precede MS diagnosis by several years, supporting a prodromal phase to the disease and improving our clinical knowledge of early MS. Integrating these symptoms in the diagnostic procedure may help earlier disease identification.
accounts of typical MS symptoms) are increasingly recognized. 3 Interestingly, a Norwegian study has shown that MS patients can have reduced cognitive performance up to 2 years prior to the first clinical event. 4 By using health administrative data from 4 Canadian provinces, a recent study has also observed that MS patients seek medical care more often than controls in the 5 years prior to a first demyelinating event. 5 However, the medical reasons behind increased medical access before diagnosis remain unknown. These observations carry pathophysiological and potential clinical implications, because early treatment and cumulative exposure to disease-modifying therapies influence MS outcome in the long term. 6, 7 Furthermore, studies on RIS have shown that compensatory mechanisms can eventually fail, leading to neurological symptoms and even primary progressive MS, 3 highlighting the importance of early recognition of disease. The few studies investigating potential prodromal symptoms of MS are hampered by small sample sizes, lack of controls, and retrospective designs with a high risk of recall bias. [8] [9] [10] We attempted to address these issues by investigating prediagnostic MS symptoms in primary care settings using prospectively collected data from a large number of patients and matched controls from the UK within the Clinical Practice Research Datalink (CPRD).
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Subjects and Methods
Study Population
We conducted a population-based observational nested casecontrol study using data from the UK's CPRD (previously known as General Practice Research Database [GPRD] ). This is a governmental, not-for-profit research service, collecting and providing upon request anonymous primary care data from electronic health records since 1987 (https://www.cprd.com/ intro.asp). 11 This dataset contains prospective, routinely collected demographic and clinical information including diagnoses, symptoms, medications, and tests. Validation studies have been performed supporting the reliability and quality of CPRD data and CPRD-coded diagnoses, including MS. 2, 12 The study was approved by the Independent Scientific Advisory Committee of the CPRD.
Study Design and Selection of Cases and Controls
This was a nested case-control study in which data collected within the CPRD were used to compare the occurrence of a variety of symptoms and conditions between cases (ie, individuals who will later receive a diagnosis of MS or clinically isolated syndrome [CIS] ) and controls (ie, individuals with no MS or CIS record). The initial extraction population was represented by all patients included in CPRD GOLD in March 2016. Inclusion criteria for cases were: (1) a clinical or referral MS event record with a specified read code indicating a diagnosis of MS or CIS at any time in the clinical or referral files (Supplementary Table 1 ), (2) validity of the records in terms of continuous follow-up and data recording as defined by CPRD standard criteria (Supplementary Table 2 ), (3) a defined gender (male and female only), (4) at least 1 MS event occurring within the study period (January 1, 1987 to February 28, 2016), (5) MS events occurring within the up-to-standard (UTS) follow-up period and with a minimum of 3 years of prior UTS follow-up (ie, at least 3 years of useable data prior to first MS diagnostic code; the UTS is deemed to be the date at which the practice is considered to have high-quality data based on continuity in data and death recording), and (6) MS events recorded before the CPRD derived death date. Cases were matched to up to 4 controls with no record of MS by sex, year of birth (5-year bands), general practitioner (GP) practice, and year of registration. The index date was defined as the date of the first MS code in the dataset for the cases and a matched index date for the controls.
Symptoms of Interest
More than 100,000 single unique read codes with a related medical term are available in the CPRD. This comprehensive list was systematically searched for read codes indicating symptoms or diagnoses of interest. These were represented by a variety of clinical disturbances with a particular attention to autonomic symptoms, psychiatric conditions, cognitive impairment, fatigue, and pain that did not clearly qualify as MS relapses. 13, 14 Read codes related to a similar pathological entity were grouped together. Autonomic groups of codes were "gastric symptoms" (eg, nausea, vomiting), "hiccough," "intestinal symptoms" (eg, diarrhea, flatulence, constipation), "urinary dysfunction" (eg, incontinence, retention), "anorectal sphincter dysfunction" (eg, incontinence, tenesmus), "sexual dysfunction in males" (eg, problem with erection), "sexual dysfunction in females" (eg, dyspareunia, vaginal dryness), "hypertension," "palpitations," "heart conduction dysfunction," "syncope," "cold extremities," "changes in color" (eg, flushing, being pale), "breathlessness," "abnormal lacrimation" (eg, tearing or dry eyes), "abnormal sweating," "anosmia," "loss of taste," and "rhinorrhea." Psychiatric groups of codes were "anxiety," "depression," "manic symptoms," "psychoses," "eating disorders," "insomnia," "personality disorders," "gender identity disorder," "tics," "self-harm," and "psychogenic disorders." Cognitive groups of codes were "cognitive impairment," "memory problems," "abnormal and/or change in behavior," and "fatigue." Pain-related groups of codes were "back/neck pain," "eye pain," "any type of headache," and "limb pain."
Finally, read codes related to insect bites were selected and used as negative control to be tested for association with MS. The whole list of read codes that were used in the analysis is available in Supplementary Table 3 .
Statistics and Sensitivity Analyses
We first estimated the proportion of cases and controls with a record indicating the occurrence of each category of symptoms within 0 to 2, 2 to 5, and 5 to 10 years before index date. Case/control rates were then compared, and odds ratios (ORs) with 95% confidence intervals (CIs) were generated using conditional logistic regression to take into account the case-control matching. The 0-to 2-, 2-to 5-, and 5-to 10-year periods were defined before performing analysis, and no additional time bands were tested. In this initial analysis, p values were Bonferroni corrected by number of tests (time intervals) within each symptom.
As a first sensitivity analysis, the same tests were performed in a restricted group of patients with age at index date < 40 years. Additional sensitivity analyses were also 
Results
Demographic Characteristics of Cases and Controls
A total of 10,204 MS patients fulfilled the inclusion criteria and were therefore considered for analyses (Fig 1) . Of these, 10,117 (99%) had at least 1, 9,951 (98%) had at least 2, 9,795 (96%) had at least 3, and 9,585 (94%) had at least 4 matched controls (n 5 39,448). Median age at index date was 47 years (interquartile range (Table 1 ). All patients and controls had least 2 years of follow-up, 6,105 (59.8%) cases and 23,523 (59.6%) controls had least 5 years of follow-up, and 2,309 (22.6%) cases and 8,848 (22.4%) controls had at least 10 years of follow-up before index date. In 88.6% of the cases, the index read code was a general term for MS (see Table 1 ). A restricted group of cases and controls with age at index < 40 years was used to perform a first sensitivity analysis (see Table 1 ).
Autonomic Symptoms MS patients had a significantly increased risk of presenting at 0 to 2, 2 to 5, and 5 to 10 years before index date with gastric symptoms (eg, nausea, vomiting) and urinary dysfunction (eg, incontinence, retention; Fig 2) . These associations were confirmed at 0 to 2, 2 to 5, and 5 to 10 years before index date in the sensitivity analysis performed in patients with age at index < 40 years (Table 2) . Intestinal symptoms were similarly reported more frequently in MS patients at 0 to 2, 2 to 5, and 5 to 10 years before index date (see Fig 2) . This association remained significant at 0 to 2 years and almost significant at 2 to 5 years before index date in the ANNALS of Neurology sensitivity analysis (see Table 2 ). MS patients also had an increased risk of presenting at 0 to 2, 2 to 5, but not 5 to 10 years before index date with a problem related to anorectal sphincter function. This association was unchanged in the sensitivity analysis (see Table 2 ). All remaining autonomic symptoms (hiccough, sexual dysfunction, hypertension, palpitations, heart conduction dysfunction, syncope, cold extremities, changes in color, breathlessness, abnormal lacrimation, abnormal sweating, anosmia, taste loss, and rhinorrhea) showed either nonsignificant associations or significant associations that were not confirmed in the sensitivity analysis (Supplementary Table 4) .
Pain
As compared to controls, MS patients had a higher frequency at 0 to 2, 2 to 5, and 5 to 10 years before index date of headache and back/neck pain (see Table 2 and Fig 3) . These associations were also confirmed in the sensitivity analysis performed in patients with age at index < 40 years (see Table 2 and Supplementary Table 5 ). An increased frequency of limb pain and eye pain records in MS patients was also present at 0 to 2 and 2 to 5 years before index date, and this was mostly confirmed in the sensitivity analysis (see Table 2 and Supplementary Table 5) .
Cognitive Symptoms and Fatigue MS patients did not have an increased frequency of records related to cognitive decline and abnormal/change in behavior at any time point before index date. Memory disturbances appeared more frequent in patients than controls at 0 to 2 years before index date, but this was not confirmed in the sensitivity analysis in patients with age at index < 40 years (Table 3) . Fatigue-related records were instead found with higher frequency among MS patients than controls at 0 to 2, 2 to 5, and 5 to 10 years before index date (see Table 3 and Fig 3) . This association remained significant at 0 to 2 and 2 to 5 years before index date in the sensitivity analysis (see Table 3 and Supplementary Table 6 ).
Psychiatric Symptoms MS patients had a significantly increased risk of presenting with anxiety up to 5 years and depression up to 10 years before index date (Fig 4) . These associations were confirmed in the sensitivity analysis of patients with age at index < 40 years (see Table 3 ). Insomnia was more frequent among MS patients at 0 to 2 and 2 to 5 years before index date, which was confirmed in the sensitivity analysis. The occurrence of eating disorders also appeared increased in MS as compared to controls at 0 to 2 and 5 to 10 years before index date, and this also remained significant in the sensitivity analysis (see Table 3 and Fig 4) . The risk of manic symptoms and self-harm appeared increased in patients at 0 to 2 years before index date, but this did not remain significant in the sensitivity analysis (Supplementary Table 7 ). All remaining psychiatric symptoms (psychoses, personality disorders, gender identity disorder, tics, and psychogenic disorders) showed either not significant associations or significant associations that were not confirmed in the sensitivity analysis (see Supplementary Table 7) . We found no association between stressful life events (difficulties during childhood, issues with partner, legal issues, looking after ill relatives, and sexual and other types of abuse) and following MS status (see Supplementary Table 7) .
Insect Bites
As a negative control, we compared the frequency of records related to insect bites between MS patients and matched 
Additional Sensitivity Analyses
We further validated the identified symptoms and conditions as prodromal in MS by excluding from the group of patients with age at index < 40 years those with a read code indicating a potential first demyelinating event occurring before the symptoms of interest (see Subjects and Methods and Supplementary neck pain, limb pain, anxiety, depression, insomnia, eating disorders, and fatigue were selected as prodromal symptoms of MS. We estimated the proportion of patients and controls experiencing 1, 2, 3, 4, and 5 of such symptoms at 0 to 2, 2 to 5, and 5 to 10 years before index date. There was a significant positive association between the number of symptoms recorded and following risk of MS, with a 51%, 29%, and 20% increased risk of MS for each additional symptom at 0 to 2, 2 to 5, and 5 to 10 years before index date, respectively (0-2 years: OR 5 1.51, 95% CI 5 1.47-1.55, p < 0.001; 2-5 years: OR 5 1.29, 95% CI 5 1.25-1.33, p < 0.001; 5-10 years: OR 5 1.20, 95% CI 5 1.15-1.26, p < 0.001; Supplementary Table 9) .
These results suggested prodromal symptoms recur together within MS patients more often than in controls (Fig 5) . As an example of this, we tested whether patients reporting fatigue were also at increased risk of experiencing additional prodromal symptoms. A record of fatigue was a significant risk factor for records of autonomic symptoms as a group (0-2 years: OR 5 2.08, 95% CI 5 1.68-2.56, p < 0.001; 2-5 years: OR 5 2.47, 95% CI 5 1.88-3.26, p < 0.001; 5-10 years: OR 5 1.43, 95% CI 5 0.96-2.15, p 5 0.080), psychiatric symptoms as a group (0-2 years: OR 5 2.46, 95% CI 5 2.00-3.03, p < 0.001; 2-5 years: OR 5 2.66, 95% CI 5 2.04-3.48, p < 0.001; 5-10 years: OR 5 2.45, 95% CI 5 1.68-3.57, p < 0.001), and pain symptoms as a group (0-2 years: OR 5 2.26, 95% CI 5 1.84-2.77, p < 0.001; 2-5 years: OR 5 1.89, 95% CI 5 1.45-2.47, p < 0.001; 5-10 years: OR 5 2.36, 95% CI 5 1.64-3.40, p < 0.001; all corrected by age and sex).
In terms of prediction, experiencing at least 1 such prodromal symptom provided sensitivity and specificity values of 43.6% and 79.9% at 0 to 2 years, 45.8% and 64.4% at 2 to 5 years, and 52.8% and 56.2% at 5 to 10 years before index date, respectively. When considering combinations of symptoms, the prediction capacity remained low, with area under the curve (AUC) of 58.1% (95% CI 5 57.1-59.0) at 0 to 2 years, 55.6% (95% CI 5 54.5-56.8) at 2 to 5 years, and 55.0% (95% CI 5 53.3-56.8) at 5 to 10 years before index date.
Discussion
Early diagnosis and treatment initiation represent key factors in preventing irreversible neuronal loss and disability in MS. By using prospectively collected data from one of the largest primary care databases in the world, we provide for the first time evidence for a large number of clinical disturbances occurring more often in patients than controls up to 10 years before MS diagnosis.
Autonomic symptoms are frequently reported by MS patients, but their timing of onset is less clear. 18 Sphincter dysfunction and gastrointestinal disturbances were overall more frequent in MS patients before index date, suggesting autonomic nervous system involvement since the earliest stages of disease. Nonetheless, similar evidence supports gastrointestinal symptoms being present early in the course of other neurological conditions such as Parkinson disease. 19 Changes in heart rate and blood pressure, as well as sexual dysfunction, are also frequent in MS, but their occurrence appears higher in later stages of disease and among patients with more advanced disability scores. 18, 20 Accordingly, we did not find evidence for cardiovascular symptoms and for sexual dysfunction being more frequent before index date. We also provide evidence for headache, back, neck, and limb pain being more frequently reported by MS patients than by matched controls before index date. Notably, pain is among the most prevalent and disabling symptoms in MS. Multiple sites in the body can be affected, and this variety likely reflects the multiple mechanisms potentially leading to pain in this disease, including neuropathic and/or nociceptive origins (eg, spasticity, joint, and muscle pain). 21, 22 The increased occurrence of pain before clinically overt disease highlights the potential relevance of damage within specific pain networks in the central nervous system. We did not observe an excess of cognitive impairment records. This appears to conflict with the recent observation of reduced cognitive performances up to 2 years prior to the first clinical event in Norwegian MS patients. 4 The latter study measured cognitive function using appropriate neuropsychological testing as part of conscription examinations. This type of information is not available in CPRD, and we believe our study does not represent the appropriate setting to investigate cognitive impairments in the first stages of MS, when cognitive problems are more likely to be mild and subtle. Instead, we found a striking association between symptoms related to fatigue and following MS records. Up to 80% of MS patients suffer from fatigue, and this can heavily affect their quality of life. 23, 24 Fatigue also appears to be frequent since the earliest stages of the disease, including patients with CIS and RIS. 25, 26 Our results are consistent with these findings and extend them in the prediagnostic phase. Psychiatric comorbidities are also extremely common in MS, with a particularly high prevalence of anxiety and depression. 27 One debated key question is whether psychiatric symptoms represent only a psychological reaction to being diagnosed with MS, side effects of therapies such as interferons, or also a primary symptom of disease. This latter hypothesis would be supported by a higher frequency of psychiatric symptoms even in the prediagnostic phase. We observed that MS patients were significantly more likely to present depression and anxiety up to 10 years before the first record of disease. Similarly, MS patients were more likely to suffer from insomnia up to 5 years prior to MS, and suggestive evidence for an increased risk of MS was also present for eating disorders. Instead, the occurrence of other psychiatric conditions was not significantly augmented. In particular, a recent study suggested an increased risk of MS in individuals with gender identity disorders, but this was not confirmed in our data. 28 Our results are consistent with those of a Swedish study of smaller sample size in which MS patients had an increased risk of being diagnosed with depression and anxiety as well as being prescribed with antidepressant and anxiolytic drugs in the 2 years preceding diagnosis. 29 We confirm and extend these results in a larger sample size and up to 10 years before diagnosis. Notably, we did not find evidence for stressful life events and later risk of MS. This makes it unlikely that an increased occurrence of traumatic events before disease onset could be responsible for the observed high psychiatric comorbidity in MS. Notably, we observed that the risk of developing MS was directly related to the number of prediagnostic symptoms that were presented, an interesting finding suggesting that such symptoms tend to recur together within MS patients more than expected. For example, we observed that reporting fatigue was a significant risk factor for also experiencing autonomic, psychiatric, and pain symptoms. Despite this, the ability to predict the future development of MS remained low, with AUC < 60%.
The strengths of this study are represented by: (1) the large sample size allowing enough statistical power to detect associations of small magnitude; (2) the use of data being routinely and prospectively collected within the CPRD, which makes the risk of recall bias unlikely; (3) the large variety of symptoms and conditions coded in the CPRD, which allowed us to investigate a wide range of clinical disturbances; and (4) the availability of a large number of controls who were accurately matched to cases by sex, age, GP practice, and year of registration.
The need of a large sample size and prospective data makes it difficult to perform such studies in secondary/tertiary care settings. We had no access to data collected by neurologists, and information regarding diagnostic criteria is lacking. This carries a potential risk of MS misdiagnosis, and the application of different diagnostic criteria could also influence how timely a definite diagnosis is made and therefore our results. Alonso et al investigated MS incidence in the UK between 1993 and 2000 by using data from the GPRD and validating diagnoses by using available medical records. 2 A total of 930 patients were initially identified as potential incident cases of MS; detailed medical records were available for 632 patients. Of these, 82.4% had a confirmed diagnosis of MS and 9.3% of possible MS, whereas for only 8.2% individuals there was no evidence of MS. 2 The CPRD represents an evolution of the GPRD, and we can therefore expect diagnostic accuracy to be similar and most diagnoses to be correct. Similarly, prodromal symptoms and their categories lack stringent definitions, due to the nature of the data and the need of a large sample size to detect associations of small magnitude. As to the potential influence of different diagnostic criteria, the observed associations were largely consistent across 3 time intervals 
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We were also limited by the need of using the date of first MS record as a proxy for the date of diagnosis, and some discrepancies are likely. We attempted to limit this potential bias by including in the analysis only individuals with a minimum of 3 years of prior UTS followup, and by performing a first sensitivity analysis in which only patients with age at index date < 40 years were tested. The median age at index date in this restricted group was 34 years (IQR 5 30-37), which closely mirrors the peak of MS incidence in the UK found by Alonso et al (35-44 years). 2 We have also performed a sensitivity analysis by further excluding those individuals with records of symptoms potentially indicating a first demyelinating event occurring before the symptoms of interest. Notably, all our main results were consistent between the overall and the sensitivity analyses, and autonomic symptoms, pain, fatigue, and psychiatric conditions remained more frequent among MS patients with no evidence of neurological disturbances. This study was only based on data from the UK, and additional studies may be needed to confirm these findings in other countries. However, we do not believe these results are specific to the UK, because the presence of prodromal symptoms in MS has also been suggested by studies performed in Canada, Norway, and Sweden. 4, 5, 29 Finally, there is also a potential risk of surveillance bias, whereby individuals with increased medical attention receive higher rates of medical diagnoses, including MS. However, no association with MS was found for most of the symptoms and conditions that were tested, as well as for insect bite records (used as a negative control). Furthermore, psychiatric, autonomic, pain, and fatigue symptoms remained more frequently reported by MS patients before first MS record even when the analysis was limited to individuals with an average number of medical contacts of at least 2 per year. This shows the observed associations are not mediated by controls with fewer medical encounters and that surveillance bias is unlikely to fully explain our findings.
To conclude, we provide the first and largest study ever performed in primary care settings investigating prediagnostic symptoms of MS. We found evidence for a variety of symptoms and conditions preceding the first MS record by GPs by up to 10 years. We highlight the increased occurrence of autonomic, pain, fatigue, and psychiatric symptoms several years before diagnosis, with the highest risk of MS among those individuals presenting combinations of these clinical disturbances. These results improve our clinical knowledge of early MS, suggesting how less specific symptoms should be interpreted in the context of this disease. Despite being unspecific and of low predictive value, we suggest their integration in the context of individual patients may aid early diagnosis and patients' care.
